Financial Performance - Ligand Pharmaceuticals reported total GAAP revenue of $268 million for 2025, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [15][16] - Full-year royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products such as FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] - Adjusted EPS increased to $8.13, up 42% year-over-year, indicating strong operating leverage and higher royalty contributions [15][16] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [16][17] - Ohtuvayre reported net sales of $178 million in Q4, with full-year sales of $506 million, marking a strong launch in COPD history [17][34] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17][18] Market Performance - Ligand's royalty portfolio is expected to see a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] - The company anticipates significant commercial opportunities in Japan for FILSPARI, with a sizable market for IgAN [71] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a systematic portfolio management strategy to drive value across partnerships [9][10][22] - The demand for royalty financing has doubled over the last five years, positioning Ligand favorably within the biopharmaceutical royalty financing sector [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong trial results for QTORIN rapamycin and the successful partnership with Leona Bio for lasofoxifene [36] - The company is optimistic about the upcoming year, expecting multiple catalysts from its late-stage development pipeline [36][31] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company reaffirmed its 2026 financial guidance, expecting adjusted EPS of approximately $8-$9 per share and royalty revenue of $200 million-$225 million [20][21] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][50] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size will increase, focusing on high clinical value assets [58][59]

Financial Data and Key Metrics Changes - Full-year adjusted EPS exceeded original 2025 guidance by more than 30%, with a 42% increase year-over-year [6][7] - Total GAAP revenue for 2025 was $268 million, up from $167 million in 2024, with core revenue reflecting a 43% year-over-year growth at $240 million [15][16] - Royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products like FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] Business Line Data and Key Metrics Changes - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total annual sales of $322 million [16][17] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales just under $200 million [17] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17] Market Data and Key Metrics Changes - The royalty funding market has doubled over the last five years, indicating a growing demand for royalty capital [10][11] - Ligand expects a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] Company Strategy and Development Direction - Ligand is focused on disciplined investments to create new, clinically differentiated product royalty streams and enhance long-term shareholder value [8][9] - The company launched a systematic portfolio management strategy to proactively communicate with partners and identify new investment opportunities [22][23] - Ligand aims to expand its business development efforts and deepen its pipeline, with a strong capital base to support growth initiatives [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and disciplined capital deployment approach, positioning the company for sustained long-term growth [12][13] - The company anticipates significant commercial upside from products like FILSPARI and Ohtuvayre, with ongoing efforts to engage with regulatory bodies for approvals [34][35] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company is optimistic about the potential of lasofoxifene and QTORIN rapamycin, with significant market opportunities projected [24][29] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][49] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size sought will increase, focusing on high clinical value assets [58][59] Question: Market size opportunity for FILSPARI in IgAN and FSGS - Management estimated consensus market size for both indications at around $1 billion, with potential royalties of approximately $90 million for each [70][71]

Financial Performance - In 2025, Ligand Pharmaceuticals achieved total GAAP revenue of $268 million, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [12][13] - Full-year adjusted EPS increased to $8.13, a 42% rise year-over-year, driven by strong operating leverage and higher royalty contributions [13][10] - Royalty revenue grew to $161 million, marking a 48% increase year-over-year, primarily from FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [12][5] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [13][14] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales of nearly $200 million [14] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [15] Market Data - The royalty financing market has doubled over the last five years, indicating a growing demand for royalty capital [9] - Ligand expects a compound annual growth rate of 23% in royalty receipts from 2025 through 2030, driven by contributions across its portfolio [10] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a strong emphasis on proactive portfolio management [6][19] - The company is positioned uniquely within the biopharmaceutical royalty financing sector, capitalizing on high demand for capital [9] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and the disciplined capital deployment approach, which positions the company for sustained long-term growth [11][33] - The company anticipates a strong pipeline of late-stage development programs and is optimistic about upcoming regulatory decisions and market expansions [33][27] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [17] - The company is actively engaged in monetizing older assets and exploring new investment opportunities across its portfolio [41][42] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and Lasofoxifene, with robust updates expected in the coming quarters [37] Question: Update on monetizing older assets - Management confirmed ongoing engagement with 5 to 10 opportunities for monetization and expects announcements by year-end [41] Question: Market opportunity for TZIELD - Management acknowledged the low royalty but emphasized the potential blockbuster opportunity with Sanofi's TZIELD, particularly in Stage 3 Type 1 diabetes [46] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS approval delay would have a negligible impact on the 2026 guidance, with a modest $4 million contribution assumed [51][63] Question: Differentiation of Castle Creek technology - Management discussed the potential advantages of the Castle Creek treatment over competitors, emphasizing its injectable nature and broader application [58]